Navigation Links
New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting

About QUADRAMET

QUADRAMET is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. This press release references clinical applications that differ from that reported in the QUADRAMET package insert.

QUADRAMET pairs the targeting ability of a small molecule, bone-seeking phosphonate (EDTMP) with the therapeutic potential of radiation (samarium Sm-153). Skeletal invasion by prostate, breast, multiple myeloma, and other cancers often creates an imbalance between the normal process of bone destruction and formation. QUADRAMET selectively targets such sites of imbalance, thereby delivering radioactivity to areas of the skeleton that have been invaded by metastatic tumor.

QUADRAMET has demonstrated a range of characteristics that may be advantageous for the treatment of pain arising from metastatic bone disease, including early onset of pain relief (patients may experience pain relief within the first week with maximal relief generally occurring at three to four weeks after injection), length of pain relief, lasting a median of four months in responding patients, and predictable and reversible bone marrow toxicity or myelosuppression that tends to return to pretreatment levels after eight weeks. QUADRAMET is administered as a single intravenous injection, usually on an outpatient basis, and exhibits selective uptake in areas of bone formation with little or no detectable accumulation in soft tissue.

QUADRAMET Safety Profile

QUADRAMET causes bone marrow suppression. In clinical trials, white blood cell counts and platelet counts decreased to a nadir of approximately 40% to 50% of baseline in 123 (95%) of patients within 3 to 5 weeks after QUADRAMET, and tended to return to pretreatment levels by 8 weeks. Because of the unknown potential for additive effects on bone marrow, QUADRAMET should not be given concurrently with chemotherapy or external beam radiati
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Preclinical Data on Cytogens Technology to be Reported at the AACR Annual Meeting
2. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
7. VEGF Trap-Eye Phase 2 Wet AMD Results Reported at ARVO Annual Meeting
8. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
9. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
10. Positive Interim Phase 2 Data Reported for VEGF Trap-Eye in Age-Related Macular Degeneration
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data for Cytogen QUADRAMET Reported Annual ASCO Meeting
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... BOTHELL, Wash. , Oct. 30, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... Company,s third quarter 2014 financial results will be released ... will host a conference call and live webcast at ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:10/30/2014)... 30, 2014 Five months after their ... Street LLC announces new branding and a website to ... . After David Mepham’s promotion to name partner earlier ... website to include Mepham’s name and better reflect their ... mediation firm, the decision to implement new branding reflects ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager ... help people save money through its innovative discount card ... drugs in the new health care system, the Paramount ... the relationship between consumers, businesses and the pharmacy industry. ... face today with medical costs is the rising price ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... prostate cancer who also have certain heart problems may increase ... study suggests. , , The therapy in question is called androgen ... levels of male hormones to prevent the growth of cancer ... this hormone therapy was linked to triple the risk of ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... in Liberia -- one of three West African nations ravaged ... officials said Wednesday. Dr. Bruce Aylward, WHO,s assistant director ... burials in Liberia and no increase in laboratory-confirmed cases. He ... tame the epidemic may be making some progress, The ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
Breaking Medicine News(10 mins):Health News:Hodgkinson Street Mepham Rebrands 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 2Health News:Ebola Outbreak in Liberia May Be Slowing: WHO 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Advisors Transitioning to Independence, SAN FRANCISCO, ... new relationship with national human resources,outsourcing company ... for,independent investment advisors and their employees. As ... advisors who custody,assets with Schwab will now ...
... 15 Dong-A PharmTech Co. Ltd,announced today the signing ... to market in Russia Dong-A,s erectile,dysfunction drug which is ... Under the terms of the agreement, Otechestvennye Lekarstva ... both upfront fees and,running royalty on sales for the ...
... as well, 266,604 fewer patients would die annually, survey ... in the top-ranked hospitals in the United States are ... the lowest-rated hospitals, according to a new study from ... HealthGrades Hospital Quality in America Study looked at 41 ...
... scientists this month joined Biomoda, Inc. (OTC Bulletin ... assist with,commercialization efforts of the company,s early lung ... "Constance Dorian brings strong analytical skills and significant,understanding ... She will be an important asset in all ...
... Researchers and Health Professionals Gather at Mental ... November 2nd, NEW YORK, Oct. 15 In ... Long Island Mental Illness,Awareness Day presented by Clubhouse of ... at the Huntington Hilton in Melville, NY from 8:00,AM ...
... fifth of patients need to work through mental problems ... -- About one in every five people who were ... recommended psychiatric clearance for the procedure, a U.S. study ... screening process in most bariatric surgery programs, notes a ...
Cached Medicine News:Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 3Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 4Health News:Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia 2Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Two Scientists Join Team of Biomoda, Inc. 2Health News:Clubhouse of Suffolk to Host 15th Annual Mental Illness Awareness Day 2Health News:Psychiatric Woes Can Postpone Weight-Loss Surgery 2
Stainless steel plain Steinman Pins available in point types A through F....
Full pin skeletal traction pins with cove point....
Calibrated Guide Pins have a 12.7 mm calibration and are available in plain, with a threaded tip, or with a trocar point....
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
Medicine Products: